Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ruud Dings to Angiogenesis Inhibitors

This is a "connection" page, showing publications Ruud Dings has written about Angiogenesis Inhibitors.

 
Connection Strength
  
 
 
4.026
  
  1. Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. Int J Mol Sci. 2017 Dec 09; 18(12).
    View in: PubMed
    Score: 0.528
  2. Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013 Mar; 344(3):589-99.
    View in: PubMed
    Score: 0.374
  3. Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem. 2010 Jan; 21(1):20-7.
    View in: PubMed
    Score: 0.305
  4. Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008 Jul 08; 265(2):270-80.
    View in: PubMed
    Score: 0.270
  5. Dings RP, Mayo KH. A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res. 2007 Oct; 40(10):1057-65.
    View in: PubMed
    Score: 0.257
  6. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007 Jun 01; 13(11):3395-402.
    View in: PubMed
    Score: 0.255
  7. Griffin RJ, Molema G, Dings RP. Angiogenesis treatment, new concepts on the horizon. Angiogenesis. 2006; 9(2):67-72.
    View in: PubMed
    Score: 0.242
  8. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst. 2006 Jul 05; 98(13):932-6.
    View in: PubMed
    Score: 0.239
  9. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer. 2005 Jun 10; 115(2):312-9.
    View in: PubMed
    Score: 0.222
  10. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003 May 08; 194(1):55-66.
    View in: PubMed
    Score: 0.192
  11. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003 Jan 15; 63(2):382-5.
    View in: PubMed
    Score: 0.188
  12. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis. 2003; 6(2):83-91.
    View in: PubMed
    Score: 0.188
  13. Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, Thijssen VLJL, Jonasch E, Vyth-Dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2023 05; 26(2):279-293.
    View in: PubMed
    Score: 0.186
  14. L?ppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Gr?ll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 2015 Jan 07; 89:279-95.
    View in: PubMed
    Score: 0.106
  15. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res. 2011 May 15; 17(10):3134-45.
    View in: PubMed
    Score: 0.082
  16. Amano M, Suzuki M, Andoh S, Monzen H, Terai K, Williams B, Song CW, Mayo KH, Hasegawa T, Dings RP, Griffin RJ. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol. 2007 Feb; 12(1):42-7.
    View in: PubMed
    Score: 0.063
  17. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006 Oct 27; 349(3):1073-8.
    View in: PubMed
    Score: 0.060
  18. Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW. Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun. 2005 Aug 12; 333(4):1261-8.
    View in: PubMed
    Score: 0.056
  19. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem. 2003 Nov 14; 278(46):45746-52.
    View in: PubMed
    Score: 0.049
  20. Dings RP, Arroyo MM, Lockwood NA, van Eijk LI, Haseman JR, Griffioen AW, Mayo KH. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J. 2003 Jul 01; 373(Pt 1):281-8.
    View in: PubMed
    Score: 0.049
  21. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002 Dec; 16(14):1991-3.
    View in: PubMed
    Score: 0.046
  22. Griffin RJ, Koonce NA, Dings RP, Siegel E, Moros EG, Br?uer-Krisch E, Corry PM. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiat Res. 2012 Jun; 177(6):804-12.
    View in: PubMed
    Score: 0.022
  23. Saarinen NM, W?rri A, Dings RP, Airio M, Smeds AI, M?kel? S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008 Sep 01; 123(5):1196-204.
    View in: PubMed
    Score: 0.017
  24. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 2007 Apr 15; 67(8):3683-90.
    View in: PubMed
    Score: 0.016
  25. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004 Oct 01; 299(2):286-93.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.